

# SUPPLEMENTARY DATA

## Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents


*Zsolt Szűcs, Viktor Kelemen, Son Le Thai, Magdolna Csávás, Erzsébet Róth, Gyula Batta,  
Annelies Stevaert, Evelien Vanderlinden, Lieve Naesens, \*Pál Herczegh\* and Anikó Borbás\**

### Table of Contents


NMR Data for glycopeptide derivatives ( <b>Tables S1-S5, Figures S1-S9</b> ).....	S2
Table of anti-coronavirus activity ( <b>Table S6</b> ).....	S20
Elementary analysis data for glycopeptide derivatives ( <b>Table S7</b> ) .....	S21
NMR spectra of compounds.....	S22

**Table S1.**  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for teicoplanin pseudoaglycon bis-alkylthio maleimide derivatives **13**, **14** and **17** (Series 1)

assignment	chemical shifts in ppm					
	<b>13</b>		<b>14</b>		<b>17</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	56.9	6.11	56.9	6.11	56.9	6.10
x2	55.5	5.00	55.5	5.00	55.5	4.98
x3	57.8	5.31	57.8	5.32	57.8	5.32
x4	54.5	5.65	54.5	5.66	54.5	5.66
x5	53.4	4.34	53.4	4.34	53.4	4.34
x6	60.8	4.12	60.8	4.13	60.8	4.10
x7	59.1	4.30	59.1	4.32	59.0	4.30
1e	118.2	6.92	118.1	6.94	118.2	6.92
2e	124.8	7.23	124.8	7.23	124.8	7.22
3b	109.7	6.34	109.7	6.34	109.7	6.33
3f	102.2	6.50	102.1	6.49	102.1	6.50
4b	107.8	5.59	107.8	5.59	107.8	5.58
5f	125.1	6.65	125.2	6.65	125.2	6.64
6b	128.3	7.86	128.3	7.86	128.4	7.86
7f	107.7	6.50	107.7	6.49	107.8	6.49
z6	75.4	5.43	75.7	5.40	75.0	5.46
z2 (z'2)	36.8	2.78/3.26	36.8	2.77/3.25	36.9	2.77/3.24
GlcNAc 1	98.6	4.39	98.9	4.38	98.3	4.40
GlcNAc CH <sub>3</sub>	22.8	1.84	22.9	1.84	22.8	1.83
MI 2,5	165.2	-	165.9	-	165.9	-
MI 3,4	135.3	-	n.d.	-	n.d.	-
Propyl 1	-	-	-	-	32.7	3.25/3.15
Propyl 2	-	-	-	-	23.2	1.56
Propyl 3	-	-	-	-	12.5	0.92
Butyl 1, 1'	30.4	3.19/3.25	-	-	-	-
Butyl 2, 2'	31.7	1.53	-	-	-	-
Butyl 3, 3'	20.6	1.34	-	-	-	-
Butyl 4, 4'	13.1	0.86	-	-	-	-
Hexyl 1, 1'	-	-	30.7	3.19/3.23	-	-
Hexyl 2, 2'	-	-	29.7	1.53	-	-
Hexyl 3, 3'	-	-	27.1	1.32	-	-
Hexyl 4, 4'	-	-	30.4	1.22	-	-
Hexyl 5, 5'	-	-	21.7	1.23	-	-
Hexyl 6, 6'	-	-	13.6	0.84	-	-
Dodecyl 1	-	-	-	-	30.8	3.23/3.17
Dodecyl 2	-	-	-	-	29.7	1.55
Dodecyl 3	-	-	-	-	27.4	1.32
Dodecyl 4-9	-	-	-	-	29.1-28.1	1.25-1.20
Dodecyl 10	-	-	-	-	31.1	1.22
Dodecyl 11	-	-	-	-	21.9	1.25
Dodecyl 12	-	-	-	-	13.7	0.85



**Figure S1.** Atom numberings of teicoplanin pseudoaglycon for NMR assignment (used for all derivatives)



**Figure S2.** Atom numberings of Series 1 side chains for NMR assignment

**Table S2.**  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for the triazole linked bis-alkylthio maleimide derivative **28** of teicoplanin pseudoaglycon (Series 2)

chemical shifts in ppm		
<b>28</b>		
assignment	$^1\text{H}$	$^{13}\text{C}$
x1	64.1	7.06
x2	55.5	4.87
x3	58.4	5.39
x4	54.7	5.62
x5	53.6	4.36
x6	60.9	4.14
x7	59.3	4.32
1b	119.6	7.01
1e	119.1	6.94
1f	125.7	6.83
2b	131.0	7.19
2e	125.2	7.15
2f	129.3	7.62
3b	110.1	6.33
3d	105.0	6.36
3f	104.0	6.54
4b	108.1	5.52
4f	104.6	5.08
5e	116.6	6.65
5f	125.5	6.63
6b	128.5	7.85
6e	123.4	7.26
6f	128.2	7.25
7d	101.7	6.30
7f	107.9	6.50
z6	76.1	5.40
z2/z'2	36.4	2.83/3.27
GlcNAc1	99.1	4.37
GlcNAc2	55.8	3.51
GlcNAc3	73.4	3.39
GlcNAc4	70.0	3.22
GlcNAc5	76.9	3.08
GlcNAc6	60.3	3.60
GlcNAc CH <sub>3</sub>	23.0	1.84
Triazole 4	141.9	-
Triazole 5	123.0	7.69
M 2,5	165.7	-
M 3,4	135.8	-
M CH <sub>2</sub>	33.5	4.59
Hexyl 1, 1'	31.1	3.22
Hexyl 2, 2'	29.9	1.54
Hexyl 3, 3'	27.4	1.32
Hexyl 4, 4'	30.6	1.23
Hexyl 5, 5'	21.9	1.23
Hexyl 6, 6'	13.8	0.83



**Table S2.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data\* for the triazole linked bis-alkylthio maleimide derivatives **26**, **27** of teicoplanin pseudoaglycon (Series 2)

assignment	chemical shifts in ppm			
	<b>26</b>		<b>27</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	64.4	7.01	64.4	7.04
x2	55.3	4.93	55.5	4.88
x3	58.6	5.35	58.5	5.37
x4	54.6	5.59	54.8	5.61
x5	53.5	4.35	53.7	4.34
x6	60.9	4.11	61.1	4.13
x7	59.4	4.28	59.5	4.30
1e	118.9	6.87	119.2	6.92
2e	124.5	7.04	125.0	7.11
3b	109.8	6.30	110.2	6.32
3f	103.8	6.57	104.1	6.53
4b	107.9	5.53	108.1	5.52
5f	125.3	6.61	125.6	6.64
6b	128.5	7.85	128.7	7.84
7f	108.0	6.49	108.1	6.48
z6	75.4	5.44	76.3	5.38
z2/z'2	2.81/3.23	36.9	36.6	2.86/3.28
GlcNAc1	98.7	4.37	99.5	4.35
GlcNAc CH <sub>3</sub>	23.0	1.83	23.1	1.85
Triazole 4	141.8	-	142.0	-
Triazole 5	123.3	7.67	123.1	7.66
M 2,5	165.6	-	165.8	-
M 3,4	135.6	-	135.8	-
M CH <sub>2</sub>	33.5	4.60	33.6	4.59
Propyl 1, 1'	33.0	3.20	-	-
Propyl 2, 2'	23.4	1.56	-	-
Propyl 3, 3'	12.8	0.91	-	-
Butyl 1, 1'	-	-	30.9	3.22
Butyl 2, 2'	-	-	32.2	1.50
Butyl 3, 3'	-	-	21.1	1.31
Butyl 4, 4'	-	-	13.4	0.83


\*only signals that are crucial for identification are listed

**Table S2.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data\* for the triazole linked bis-alkylthio maleimide derivatives **29-31** of teicoplanin pseudoaglycon (Series 2)

	<b>29</b>		<b>30</b>		<b>31</b>	
assignment	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	64.6	7.05	64.7	7.01	64.0	7.07
x2	55.6	4.90	55.4	4.95	55.3	4.85
x3	58.7	5.37	58.9	5.34	58.4	5.39
x4	54.9	5.62	54.7	5.57	54.8	5.63
x5	53.9	4.35	53.6	4.36	53.7	4.34
x6	61.2	4.15	61.0	4.15	61.0	4.13
x7	59.6	4.31	59.6	4.26	59.2	4.31
1e	119.2	6.92	118.9	6.85	119.0	6.95
2e	125.0	7.11	124.6	6.99	125.3	7.14
3b	110.1	6.33	110.0	6.30	110.0	6.33
3f	104.0	6.56	103.8	6.56	103.9	6.53
4b	108.1	5.54	108.0	5.53	108.0	5.53
5f	125.6	6.65	125.5	6.62	125.4	6.63
6b	128.7	7.86	128.7	7.80	128.5	7.86
7f	108.1	6.49	108.1	6.47	107.9	6.50
z6	76.1	5.40	76.4	5.37	75.7	5.42
z2/z'2	36.7	3.27/2.85	37.3	2.78/3.21	36.1	2.88/3.29
GlcNAc1	99.3	4.38	99.7	4.34	98.9	4.38
GlcNAc CH <sub>3</sub>	23.1	1.84	23.2	1.84	22.9	1.83
<hr/>						
T4	141.8	-	142.1	-	141.9	-
T5	123.2	7.70	123.3	7.64	122.9	7.65
<hr/>						
M 2,5	165.7	-	165.8	-	165.5	-
M 3,4	135.8	-	135.9	-	135.6	-
M CH <sub>2</sub>	33.5	4.59	33.6	4.58	33.3	4.58
<hr/>						
Alkyl $\alpha/\alpha'$	31.1	3.22	31.3	3.21	-	-
Alkyl $\beta/\beta'$	30.0	1.55	30.1	1.53	-	-
Alkyl $\gamma/\gamma'$	27.8	1.33	27.8	1.31	-	-
Alkyl bulk**	28.5	1.22	29.1	1.21	-	-
Alkyl $\omega$ -2/ $\omega$ -2'	31.3	1.21	31.4	1.21	-	-
Alkyl $\omega$ -1/ $\omega$ -1'	22.1	1.23	22.2	1.23	-	-
Alkyl $\omega/\omega'$	14.0	0.84	14.0	0.83	-	-
<hr/>						
$\alpha$ -G1	-	-	-	-	95.8	5.38
$\alpha$ -G2	-	-	-	-	69.7	4.31
$\alpha$ -G3	-	-	-	-	70.2	4.59
$\alpha$ -G4	-	-	-	-	71.0	4.20
$\alpha$ -G5	-	-	-	-	67.3	3.80
$\alpha$ -G6	-	-	-	-	31.3	3.44 / 3.26
$\alpha$ -G-C <sub>q</sub>	-	-	-	-	108.0/108.6	-
$\alpha$ -G-CH <sub>3</sub>	-	-	-	-	25.6	1.28
	-	-	-	-	24.4	1.23

\*only signals that are crucial for identification are listed

\*\*  $\delta$  to  $\omega$ -3 methylene groups of alkyl substituents



**Figure S3.** Atom numberings of Series 2 side chains for NMR assignment  
(This structure is only an illustration)

**Table S3.** <sup>1</sup>H and <sup>13</sup>C NMR data for the triazole-tetraethylene glycol linked bis-alkylthio maleimide derivative **42** of teicoplanin pseudoaglycon (Series 3)

<b>42</b>					
assignment	<sup>1</sup> H	<sup>13</sup> C	assignment	<sup>1</sup> H	<sup>13</sup> C
x1	7.07	64.3	GlcNAc1	4.39	98.8
x2	4.91	55.4	GlcNAc2	3.52	55.9
x3	5.36	58.5	GlcNAc3	3.37	73.5
x4	5.61	54.7	GlcNAc4	3.20	69.9
x5	4.35	53.6	GlcNAc5	3.08	76.9
x6	4.13	61.0	GlcNAc6	3.58	60.3
x7	4.30	59.4	GlcNAc CH <sub>3</sub>	1.83	23.0
1b	6.99	119.8			
1e	6.89	119.0	TEG a	4.44	63.4
1f	6.80	125.7	TEG h	3.49	66.9
2b	7.17	130.8	TEG i	3.55	37.8
2e	7.10	124.8	TEG bulk	3.48-3.38	70.0-69.0
3b	6.32	109.9			
3d	6.33	104.8	Triazole 4	-	143.7
3f	6.56	103.9	Triazole 5	7.71	124.2
4b	5.53	108.0			
4f	5.08	104.6	M 2,5	-	166.1
5e	6.61	116.5	M 3,4	-	135.5
5f	6.63	125.4			
6b	7.84	128.6	Hexyl 1, 1'	3.23	31.1
6e	7.25	123.3	Hexyl 2, 2'	1.55	30.0
6f	7.25	128.0	Hexyl 3, 3'	1.34	27.4
7d	6.27	101.6	Hexyl 4, 4'	1.24	30.7
7f	6.49	108.1	Hexyl 5, 5'	1.24	22.0
z6	5.43	75.7	Hexyl 6, 6'	0.84	13.9
z2/z'2	3.28/2.85	36.7			

**Table S3.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data\* for the triazole-tetraethylene glycol linked bis-alkylthio maleimide derivatives of teicoplanin pseudoaglycon **40-46** (Series 3)

assignment	chemical shifts in ppm			
	<b>40</b>		<b>41</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	64.3	7.06	64.1	7.07
x2	55.4	4.90	55.3	4.89
x3	58.5	5.37	58.3	5.37
x4	54.7	5.61	54.6	5.61
x5	53.7	4.34	53.5	4.35
x6	61.0	4.12	60.8	4.14
x7	59.2	4.32	59.3	4.29
1e	119.1	6.90	118.9	6.91
2e	124.6	7.10	124.8	7.11
3b	110.0	6.32	109.9	6.32
3f	104.0	6.57	103.8	6.55
4b	108.1	5.54	107.9	5.53
5f	125.4	6.63	125.2	6.63
6b	128.6	7.86	128.4	7.84
7f	108.2	6.52	107.9	6.48
z6	75.2	5.44	75.8	5.41
z2/z'2	36.7	2.86/3.28	36.5	2.86/3.28
GlcNAc1	98.4	4.39	98.9	4.38
GlcNAc CH <sub>3</sub>	23.1	1.84	22.9	1.83
Triazole 4	143.7	-	n.d.	-
Triazole 5	124.2	7.71	124.5	7.72
M 2,5	166.0	-	n.d.	-
M 3,4	135.4	-	n.d.	-
TEG a	63.4	4.44	63.2	4.43
TEG h	66.9	3.50	66.7	3.49
TEG i	37.8	3.55	37.7	3.55
TEG bulk	70.2-69.2	3.49-3.41	69.8-68.8	3.49-3.41
Propyl 1, 1'	33.0	3.22	-	-
Propyl 2, 2'	23.5	1.59	-	-
Propyl 3, 3'	12.8	0.93	-	-
Butyl 1, 1'	-	-	30.7	3.23
Butyl 2, 2'	-	-	32.0	1.54
Butyl 3, 3'	-	-	20.9	1.36
Butyl 4, 4'	-	-	13.3	0.85

\*only signals that are crucial for identification are listed

**Table S3.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data\* for the triazole-TEG linked bis-alkylthio maleimide derivatives of teicoplanin pseudoaglycon **40-46** (Series 3)

assignment	chemical shifts in ppm			
	<b>43</b>		<b>44</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	64.6	7.04	64.2	7.08
x2	55.4	4.96	55.5	4.87
x3	58.8	5.35	58.4	5.39
x4	54.7	5.59	54.8	5.63
x5	53.6	4.35	53.7	4.34
x6	61.0	4.16	61.1	4.12
x7	59.5	4.27	59.1	4.33
1e	119.0	6.88	119.2	6.95
2e	124.7	7.03	125.0	7.17
3b	110.0	6.31	110.2	6.34
3f	103.9	6.56	104.1	6.54
4b	108.0	5.53	108.2	5.54
5f	125.8	6.63	125.6	6.64
6b	128.7	7.81	128.7	7.85
7f	108.1	6.50	107.8	6.45
z6	76.4	5.36	75.8	5.40
z2/z'2	37.2	2.83/3.25	36.4	2.90/3.31
GlcNAc1	99.6	4.35	99.0	4.38
GlcNAc CH <sub>3</sub>	23.2	1.84	23.1	1.83
Triazole 4	143.7	-	143.8	-
Triazole 5	124.3	7.68	124.1	7.72
M 2,5	166.1	-	166.1	-
M 3,4	135.6	-	135.6	-
TEG a	63.5	4.43	63.4	4.43
TEG h	67.0	3.49	67.0	3.49
TEG i	37.9	3.54	37.8	3.55
TEG bulk	69.8-68.9	3.49-3.39	69.8-69.0	3.49-3.39
Alkyl $\alpha$ , $\alpha'$	31.2	3.22	31.1	3.22
Alkyl $\beta$ , $\beta'$	30.2	1.55	30.1	1.55
Alkyl $\gamma$ , $\gamma'$	27.9	1.32	27.8	1.33
Alkyl bulk**	28.7	1.22	29.0	1.21
Alkyl $\omega$ -2	31.3	1.21	31.4	1.20
Alkyl $\omega$ -1	22.3	1.25	22.1	1.24
Alkyl $\omega$	14.1	0.83	13.9	0.84


\*only signals that are crucial for identification are listed

\*\*  $\delta$  to  $\omega$ -3 methylene groups of alkyl substituents

**Table S3.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data\* for the triazole-TEG linked bis-alkylthio maleimide derivatives of teicoplanin pseudoaglycon **40-46** (Series 3)

assignment	chemical shifts in ppm			
	45		46	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	64.5	7.06	63.9	7.09
x2	55.2	4.96	55.4	4.84
x3	58.6	5.35	58.2	5.39
x4	54.4	5.59	54.6	5.67
x5	53.4	4.37	53.7	4.29
x6	60.7	4.17	60.9	4.12
x7	59.3	4.27	57.4	4.39
1e	118.9	6.89	119.1	6.94
2e	124.6	7.03	125.0	7.20
3b	109.8	6.32	110.2	6.33
3f	103.7	6.58	104.0	6.52
4b	108.0	5.54	108.2	5.53
5f	125.4	6.64	125.8	6.67
6b	128.7	7.82	128.7	7.85
7f	108.0	6.51	106.5	6.32
z6	76.2	5.37	75.5	5.33
z2/z'2	37.1	2.81/3.25	36.1	2.91/3.30
GlcNAc1	99.5	4.37	98.6	4.34
GlcNAc CH <sub>3</sub>	22.9	1.85	23.1	1.86
Triazole 4	143.7	-	143.8	-
Triazole 5	124.2	7.69	124.1	7.74
M 2,5	166.0	-	166.1	-
M 3,4	135.5	-	135.4	-
TEG a	63.3	4.44	63.2	4.43
TEG h	66.9	3.48	66.8	3.49
TEG i	37.6	3.54	37.6	3.54
TEG bulk	70.2-69.0	3.53-3.40	70.0-69.0	.50-3.41
TEG1, 1'	-	-	30.7	3.42
TEG2, 2'	-	-	69.8	3.61
TEG7, 7'	-	-	72.3	3.40
TEG8, 8'	-	-	60.2	3.47
$\alpha$ -G1	95.9	5.44	-	-
	67.4	3.83	-	-
$\alpha$ -G2-5	69.7	4.34	-	-
	70.3	4.61	-	-
	71.1	4.22	-	-
$\alpha$ -G6	31.5	3.46 / 3.29	-	-
$\alpha$ -G-C <sub>q</sub>	108.6/108.0	-	-	-
$\alpha$ -G-CH <sub>3</sub>	25.8/25.6	1.38/1.33	-	-
	24.5	1.25	-	-

\*only signals that are crucial for identification are listed



**Figure S4.** Atom numberings of Series 3 side chains for NMR assignment  
(First structure is an illustration)




**Table S4.** <sup>1</sup>H and <sup>13</sup>C NMR data for teicoplanin pseudoaglycon TEG-monoalkyl derivatives **60-63** (Series 5)

assignment	<b>60</b>		<b>61</b>	
	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H
x1	64.1	7.07	64.2	7.07
x2	55.5	4.86	55.4	4.88
x3	58.4	5.38	58.3	5.38
x4	54.7	5.62	54.8	5.62
x5	53.6	4.34	53.7	4.34
x6	61.0	4.11	61.0	4.14
x7	59.4	4.30	59.4	4.30
1e	119.1	6.93	118.9	6.93
2e	124.9	7.15	124.9	7.14
3b	110.0	6.32	110.1	6.32
3f	104.0	6.55	104.0	6.56
4b	108.0	5.52	108.1	5.53
5f	125.3	6.61	125.4	6.62
6b	128.5	7.85	128.5	7.85
7f	107.9	6.48	108.0	6.48
z6	75.6	5.43	75.9	5.41
z2/z'2	36.4	2.88/3.30	36.5	2.88/3.28
G1	98.8	4.39	99.0	4.38
G-CH <sub>3</sub>	23.1	1.82	23.1	1.83
TA 4	144.0	-	144.0	-
TA 5	124.1	7.71	124.1	7.71
TA Me	63.3	4.43	63.4	4.43
TB 4	143.8	-	143.8	-
TB 5	124.2	8.01	124.2	8.01
TB Me	63.3	4.45	63.4	4.45
TEG bulk	69.6	3.43	69.7	3.43
	69.5	3.47	69.5	3.47
TEG g	68.7	3.77	68.8	3.77
TEG h	49.3	4.49	49.4	4.48
Hexyl 1	-	-	69.6	3.39
Hexyl 2	-	-	29.2	1.47
Hexyl 3	-	-	25.4	1.25
Hexyl 4	-	-	31.2	1.22
Hexyl 5	-	-	22.1	1.23
Hexyl 6	-	-	14.0	0.83
Butyl 1	69.4	3.40	-	-
Butyl 2	31.6	1.48	-	-
Butyl 3	19.2	1.29	-	-
Butyl 4	14.1	0.85	-	-

**Table S4.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for teicoplanin pseudoaglycon TEG-monoalkyl derivatives **60-63** (Series 5)

assignment	<b>62</b>		<b>63</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	64.6	7.03	64.5	7.04
x2	55.3	4.96	55.3	4.97
x3	58.8	5.33	58.8	5.34
x4	54.6	5.57	54.5	5.58
x5	53.5	4.35	53.5	4.36
x6	60.9	4.16	60.9	4.15
x7	59.6	4.27	59.5	4.27
1e	119.0	6.85	119.0	6.86
2e	124.7	7.00	124.6	7.00
3b	109.7	6.30	109.8	6.31
3f	103.7	6.56	103.7	6.58
4b	108.0	5.53	107.9	5.53
5f	125.5	6.63	125.4	6.62
6b	128.7	7.80	128.6	7.81
7f	108.0	6.47	108.0	6.48
z6	76.2	5.36	76.2	5.38
z2/z'2	37.3	2.79/3.22	37.2	2.80/3.23
G1	99.6	4.34	99.5	4.35
G-CH <sub>3</sub>	23.1	1.84	23.0	1.84
<hr/>				
TA 4	144.1	-	143.6	-
TA 5	124.2	7.67	124.3	7.67
TA Me	63.3	4.41	63.4	4.40
TB 4	144.4	-	144.0	-
TB 5	124.2	8.01	124.3	8.01
TB Me	63.3	4.44	63.4	4.44
<hr/>				
TEG bulk	69.7	3.43	69.7	3.44
	69.6	3.47	69.5	3.48
TEG g	68.7	3.77	68.7	3.77
TEG h	49.4	4.47	49.3	4.48
<hr/>				
Decyl 1	-	-	69.6	3.39
Decyl 2	-	-	29.2	1.46
Decyl 3	-	-	25.7	1.23
Decyl 4-7	-	-	28.9	1.22
Decyl 8	-	-	31.3	1.22
Decyl 9	-	-	22.1	1.23
Decyl 10	-	-	14.0	0.84
<hr/>				
Octyl 1	69.5	3.39	-	-
Octyl 2	29.2	1.46	-	-
Octyl 3	25.6	1.25	-	-
Octyl 4-5	28.8	1.23	-	-
Octyl 6	31.3	1.20	-	-
Octyl 7	22.1	1.25	-	-
Octyl 8	13.6	0.84	-	-




**Figure S5.** Atom numberings of Series 5 side chains for NMR assignment

**Table S5.**  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for the sulfonamide derivatives **72-79** of teicoplanin pseudoaglycon (Series 6)

assignment	chemical shifts in ppm			
	<b>72</b>		<b>73</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	58.2 <sup>a</sup>	5.27 <sup>a</sup>	58.1 <sup>a</sup>	5.27 <sup>a</sup>
x2	55.2	4.25	55.2	4.24
x3	58.0 <sup>a</sup>	5.20 <sup>a</sup>	58.1 <sup>a</sup>	5.27 <sup>a</sup>
x4	54.7	5.60	54.7	5.60
x5	53.7	4.31	53.7	4.32
x6	61.0	4.11	61.0	4.13
x7	59.0	4.32	59.3	4.32
1e	118.5	6.92	118.6	6.68
2e	124.8	7.20	124.9	7.20
3b	110.0	6.27	110.1	6.27
3f	104.3	6.39	104.4	6.39
4b	107.7	5.45	107.8	5.46
5f	125.3	6.62	125.4	6.63
6b	128.5	7.85	128.7	7.86
7f	107.8	6.46	107.9	6.50
z6	75.8	5.39	76.1	5.38
z2/z'2	35.6	2.43/3.15	36.0	2.50/3.15
G1	99.0	4.38	99.3	4.36
G-CH <sub>3</sub>	23.1	1.83	23.1	1.84
T2,6	127.1	7.73	-	-
T3,5	129.3	7.38	-	-
T-Me	21.0	2.37	-	-
BS1	-	-	140.9	-
BS2,6	-	-	127.0	7.86
BS3,5	-	-	128.9	7.59
BS4	-	-	132.6	7.64

<sup>a</sup>ambiguous




**Figure S6.** Atom numberings of Series 6 side chains for NMR assignment (for compounds **72** and **73**, respectively)

**Table S5.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for the sulfonamide derivatives **72-79** of teicoplanin pseudoaglycon (Series 6)

assignment	chemical shifts in ppm			
	<b>74</b>		<b>75</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	58.2 <sup>a</sup>	5.24 <sup>a</sup>	58.1	5.29
x2	55.6	4.29	55.3	4.27
x3	58.4 <sup>a</sup>	5.29 <sup>a</sup>	58.3	5.28
x4	54.8	5.61	54.7	5.60
x5	53.8	4.33	53.7	4.32
x6	61.1	4.14	61.0	4.13
x7	59.5	4.32	59.3	4.33
1e	118.6	6.64	118.5	6.67
2e	125.0	7.18	124.8	7.20
3b	110.1	6.28	110.1	6.26
3f	104.4	6.40	104.4	6.40
4b	107.8	5.47	107.7	5.45
5f	125.5	6.64	125.4	6.63
6b	128.3	7.84	128.6	7.86
7f	108.0	6.48	107.9	6.50
z6	76.5	5.37	75.9	5.39
z2/z'2	36.0	2.52/3.14	35.9	2.50/3.07
G1	99.6	4.38	99.1	4.36
G-CH <sub>3</sub>	23.2	1.85	23.2	1.85
<hr/>				
P1	134.4	-	-	-
P2,6	128.2	7.77	-	-
P3,5	118.4	7.77	-	-
P4	144.9	-	-	-
P7	171.9	-	-	-
P8 (NHAc)	24.3	2.09	-	-
<hr/>				
BPh1	-	-	139.6	-
BPh2,6	-	-	127.6	7.93
BPh3,5	-	-	127.0	7.89
BPh4	-	-	144.0	-
BPh7	-	-	138.6	-
BPh8,12	-	-	127.1	7.72
BPh9,11	-	-	129.3	7.52
BPh10	-	-	128.6	7.45

<sup>a</sup> ambiguous




**Figure S7.** Atom numberings of Series 6 side chains for NMR assignment (for compounds **74** and **75**, respectively)

**Table S5.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for the sulfonamide derivatives **72-79** of teicoplanin pseudoaglycon (Series 6)

assignment	chemical shifts in ppm			
	<b>76</b>		<b>77</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	58.2 <sup>a</sup>	5.21 <sup>a</sup>	58.16 <sup>a</sup>	5.34 <sup>a</sup>
x2	54.9	4.06	55.33	4.89
x3	58.2 <sup>a</sup>	5.21 <sup>a</sup>	58.16 <sup>a</sup>	5.34 <sup>a</sup>
x4	54.8	5.59	54.69	5.62
x5	53.7	4.30	53.66	4.32
x6	61.0	4.13	60.89	4.12
x7	59.3	4.33	59.20	4.30
1e	118.6	6.88	118.47	6.96
2e	124.9	7.20	124.83	7.19
3b	110.2	6.25	109.83	6.31
3f	104.2	6.34	103.83	6.41
4b	107.7	5.44	107.54	5.48
5f	125.5	6.63	125.29	6.63
6b	128.7	7.87	128.45	7.85
7f	108.0	6.50	107.83	6.48
z6	76.1	5.38	75.43	5.41
z2/z'2	36.0	2.20/3.02	36.47	2.78/3.33
G1	99.3	4.36	98.64	4.38
G-CH <sub>3</sub>	23.1	1.85	23.03	1.83
Ds2	120.0	8.36	-	-
Ds3	127.8	7.56	-	-
Ds4	115.2	7.25	-	-
Ds5	151.1	-	-	-
	129.9	8.48	-	-
Ds6-8	128.9	8.31	-	-
	123.5	7.69	-	-
Ds11-12 (NMe <sub>2</sub> )	45.2	2.82		
Hexyl 1	-	-	52.56	2.93
Hexyl 2	-	-	22.89	1.63
Hexyl 3	-	-	27.34	1.31
Hexyl 4	-	-	30.83	1.23
Hexyl 5	-	-	21.90	1.25
Hexyl 6	-	-	13.90	0.85

<sup>a</sup> ambiguous




**Figure S8.** Atom numberings of Series 6 side chains for NMR assignment (for compounds **76** and **77**, respectively)

**Table S5.** (continued)  $^1\text{H}$  and  $^{13}\text{C}$  NMR data for the sulfonamide derivatives **72-79** of teicoplanin pseudoaglycon (Series 6)

assignment	chemical shifts in ppm			
	<b>78</b>		<b>79</b>	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
x1	58.2 <sup>a</sup>	5.35 <sup>a</sup>	58.1	5.35
x2	55.4	4.88	55.3	4.91
x3	58.2 <sup>a</sup>	5.33 <sup>a</sup>	58.1	5.35
x4	54.7	5.63	54.7	5.62
x5	53.7	4.32	53.6	4.32
x6	61.0	4.15	60.9	4.13
x7	58.9	4.31	59.2	4.30
1e	118.5	7.00	118.5	6.95
2e	125.0	7.19	124.8	7.19
3b	109.9	6.30	109.8	6.31
3f	103.9	6.38	103.8	6.42
4b	107.9	5.49	107.7	5.49
5f	125.5	6.64	125.3	6.62
6b	128.6	7.85	128.5	7.86
7f	107.7	6.43	107.9	6.50
z6	76.2	5.34	75.5	5.43
z2/z'2	36.5	2.77/3.33	36.6	2.79/3.34
G1	99.4	4.35	98.7	4.39
G-CH <sub>3</sub>	23.1	1.82	23.0	1.83
Octyl 1	52.62	2.93	-	-
Octyl 2	22.98	1.63	-	-
Octyl 3	27.89	1.31	-	-
Octyl 4-5	28.71	1.23	-	-
Octyl 6	31.28	1.22	-	-
Octyl 7	22.10	1.24	-	-
Octyl 8	13.99	0.84	-	-
Dodecyl 1	-	-	52.5	2.94
Dodecyl 2	-	-	22.9	1.63
Dodecyl 3	-	-	27.6	1.31
Dodecyl 4-9	-	-	28.9	1.22
Dodecyl 10	-	-	31.2	1.21
Dodecyl 11	-	-	22.0	1.24
Dodecyl 12	-	-	13.9	0.84

<sup>a</sup> ambiguous



**Figure S9.** Atom numberings of Series 6 side chains for NMR assignment (for compounds **78** and **79**)

**Table S6.** Activity in human coronavirus 229E-infected human HEL<sup>a</sup> or A549<sup>b</sup> cells.

Compound	CPE reduction assay in HEL cells <sup>a</sup>		Virus yield assay in A549 cells <sup>b</sup>		
	EC <sub>50</sub>	MCC	EC <sub>99</sub>	EC <sub>90</sub>	MCC
μM					
<b>13</b>	5.4	≥20	10	4.1	50
<b>14</b>	5.4	≥20	9.4	5.8	50
<b>27</b>	5.4	≥20	11	5.9	>50
<b>28</b>	8.9	≥20	9.5	6.4	≥50
<b>41</b>	8.9	≥100	29	8.6	>50
<b>42</b>	5.4	≥20	21	7.6	>50
<b>60</b>	≥100	≥100	ND	ND	ND
<b>61</b>	44	≥100	44	25	>50
<b>62</b>	8.9	100	30	23	>50
<b>72</b>	5.2	≥100	10	4.9	>50
<b>73</b>	5.5	≥20	11	6.8	>50
<b>74</b>	>100	≥20	ND	ND	ND
<b>75</b>	>100	4	ND	ND	ND
<b>76</b>	>100	≥4	ND	ND	ND
<b>77</b>	1.5	20	ND	ND	ND
<b>78</b>	5.4	≥20	9.4	5.7	>50
<b>79</b>	1.8	20	4.7	2.8	50
UDA (μg/ml) <sup>c</sup>	1.8	>100	ND	ND	ND
K22 (μM) <sup>c</sup>	ND	ND	15	11	≥50

<sup>a</sup>HEL: human embryonic lung fibroblast cells. Antiviral EC<sub>50</sub>: compound concentration producing 50% inhibition of virus replication, as estimated by microscopic scoring of the cytopathic effect (CPE). MCC: minimum cytotoxic concentration, i.e. compound concentration producing minimal changes in cell morphology, as estimated by microscopy.

<sup>b</sup>A549: human lung epithelial carcinoma cells. Antiviral activity expressed as the compound concentration causing a 2-log<sub>10</sub> (EC<sub>99</sub>) and 1-log<sub>10</sub> (EC<sub>90</sub>) reduction in virus yield at 72 h p.i., as determined by real-time RT-PCR.

<sup>c</sup>Reference compounds: UDA (*Urtica dioica* agglutinin) lectin, concentration expressed in μg/ml; K22 [(Z)-N-(3-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-3-oxo-1-phenylprop-1-en-2-yl)benzamide]<sup>1</sup>, concentration expressed in μM.

Data represent the averages of two independent tests. ND, not determined.



**Table S7.** Elemental analysis data (C, H, N, S) for teicoplanin derivatives.


#	formula	C		H		N		S	
		Calcd.	Found	Calcd.	Found	Calcd.	Found	Calcd.	Found
13	C <sub>78</sub> H <sub>74</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S <sub>2</sub>	56.49	56.35	4.50	4.65	6.76	6.63	3.87	3.75
14	C <sub>82</sub> H <sub>82</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S <sub>2</sub>	57.44	57.39	4.82	5.09	6.54	6.40	3.74	3.67
17	C <sub>85</sub> H <sub>88</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S <sub>2</sub>	58.12	57.95	5.05	5.21	6.38	6.25	3.65	3.44
26	C <sub>79</sub> H <sub>73</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>25</sub> S <sub>2</sub>	55.44	55.32	4.30	4.48	9.00	8.87	3.75	3.63
27	C <sub>81</sub> H <sub>77</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>25</sub> S <sub>2</sub>	55.93	55.68	4.46	4.69	8.86	8.80	3.69	3.59
28	C <sub>85</sub> H <sub>85</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>25</sub> S <sub>2</sub>	56.85	56.57	4.77	5.02	8.58	8.45	3.57	3.51
29	C <sub>89</sub> H <sub>93</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>25</sub> S <sub>2</sub>	57.73	57.57	5.06	5.28	8.32	8.28	3.46	3.38
30	C <sub>97</sub> H <sub>109</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>25</sub> S <sub>2</sub>	59.32	59.22	5.59	5.84	7.85	7.65	3.26	3.14
31	C <sub>97</sub> H <sub>97</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>35</sub> S <sub>2</sub>	55.17	55.25	4.63	4.91	7.30	7.13	3.04	2.92
40	C <sub>87</sub> H <sub>89</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>29</sub> S <sub>2</sub>	55.36	55.18	4.75	4.98	8.16	8.10	3.40	3.29
41	C <sub>89</sub> H <sub>93</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>29</sub> S <sub>2</sub>	55.80	55.62	4.89	5.05	8.04	7.92	3.35	3.27
42	C <sub>93</sub> H <sub>101</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>29</sub> S <sub>2</sub>	56.65	55.48	5.16	5.34	7.81	7.67	3.25	3.18
43	C <sub>97</sub> H <sub>109</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>29</sub> S <sub>2</sub>	57.45	57.32	5.42	5.53	7.60	7.54	3.16	3.05
44	C <sub>105</sub> H <sub>125</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>29</sub> S <sub>2</sub>	58.93	58.70	5.89	6.02	7.20	7.11	3.00	2.91
45	C <sub>105</sub> H <sub>113</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>39</sub> S <sub>2</sub>	55.12	54.95	4.98	5.09	6.73	6.61	2.80	2.70
46	C <sub>97</sub> H <sub>109</sub> Cl <sub>2</sub> N <sub>11</sub> O <sub>37</sub> S <sub>2</sub>	54.04	53.85	5.10	5.18	7.15	7.07	2.97	2.83
60	C <sub>84</sub> H <sub>87</sub> Cl <sub>2</sub> N <sub>13</sub> O <sub>28</sub>	56.13	55.89	4.88	5.03	10.13	10.02	-	-
61	C <sub>86</sub> H <sub>91</sub> Cl <sub>2</sub> N <sub>13</sub> O <sub>28</sub>	56.58	56.35	5.02	5.11	9.97	9.80	-	-
62	C <sub>88</sub> H <sub>95</sub> Cl <sub>2</sub> N <sub>13</sub> O <sub>28</sub>	57.02	56.88	5.17	5.29	9.82	9.64	-	-
63	C <sub>90</sub> H <sub>99</sub> Cl <sub>2</sub> N <sub>13</sub> O <sub>28</sub>	57.45	57.35	5.30	5.47	9.68	9.49	-	-
72	C <sub>73</sub> H <sub>64</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S	56.34	56.32	4.15	4.36	7.20	7.08	2.06	1.95
73	C <sub>72</sub> H <sub>62</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S	56.07	56.11	4.05	4.24	7.27	7.13	2.08	1.94
74	C <sub>74</sub> H <sub>65</sub> Cl <sub>2</sub> N <sub>9</sub> O <sub>26</sub> S	55.57	55.34	4.10	4.18	7.88	7.66	2.00	1.94
75	C <sub>78</sub> H <sub>66</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S	57.89	57.95	4.11	4.22	6.92	6.75	1.98	1.90
76	C <sub>78</sub> H <sub>69</sub> Cl <sub>2</sub> N <sub>9</sub> O <sub>25</sub> S	57.29	57.32	4.25	4.50	7.71	7.44	1.96	1.88
77	C <sub>72</sub> H <sub>70</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S	55.78	55.57	4.55	4.78	7.23	7.10	2.07	1.97
78	C <sub>74</sub> H <sub>74</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S	56.31	56.08	4.73	4.88	7.10	6.98	2.03	1.96
79	C <sub>78</sub> H <sub>82</sub> Cl <sub>2</sub> N <sub>8</sub> O <sub>25</sub> S	57.32	57.04	5.06	5.11	6.86	6.82	1.96	1.91


## References


1. Lundin, A.; Dijkman, R.; Bergström, T.; Kann, N.; Adamiak, B.; Hannoun, C.; Kindler, E.; Jónsdóttir, H. R.; Muth, D.; Kint, J.; Forlenza, M.; Müller, M. A.; Drosten, C.; Thiel, V.; Trybala, E. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. *PLoS Pathog.* **2014**, *10*, e1004166.

Compound 5a  
1H

$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.07 (s, 1H), 3.29 (t,  $J = 7.3$  Hz, 4H),  
1.69 – 1.58 (m, 4H), 1.52 – 1.35 (m, 4H), 0.93 (t,  $J = 7.3$  Hz, 6H).









Compound 6a  
13C

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.61, 136.84, 31.93, 31.39, 30.55, 28.28, 22.60, 14.10.




Compound 9a  
1H


$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.60 (s, 1H), 3.34 – 3.22 (m, 4H), 1.74 – 1.59 (m, 4H), 1.45 – 1.37 (m, 2H), 1.30 – 1.21 (m, 16H), 1.03 (t,  $J = 7.4$  Hz, 3H), 0.88 (t,  $J = 6.8$  Hz, 3H).



Compound 9a  
13C


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.61, 166.40, 136.98, 136.71, 33.79, 32.04, 31.95, 30.59, 29.76, 29.69, 29.60, 29.48, 29.24, 28.62, 24.03, 22.82, 14.26, 13.23.









Compound 1a  
DMSO, 298K, <sup>13</sup>C, TXI






Compound 14  
DMSO, 298K, HSQC, TXI



f1 (ppm)


f2 (ppm)

S30




Compound 19  
1H

$^1\text{H}$  NMR (360 MHz, Chloroform-*d*)  $\delta$  4.27 (d,  $J=2.5$  Hz, 2H), 3.38 – 3.16 (m, 4H), 2.23 (t,  $J=2.5$  Hz, 1H), 1.80 – 1.60 (m, 4H), 1.03 (t,  $J=7.3$  Hz, 6H).



Compound 19  
13C

$^{13}\text{C}$  NMR (91 MHz,  $\text{CDCl}_3$ )  $\delta$  165.33, 136.07, 71.63,  
33.81, 27.56, 24.00, 13.20.




Compound 20  
1H


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.27 (d,  $J = 3.3$  Hz, 2H), 3.31 (t,  $J = 7.4$  Hz, 4H), 2.23 (t,  $J = 2.5$  Hz, 1H), 1.69 – 1.59 (m, 4H), 1.50 – 1.40 (m, 4H), 0.93 (t,  $J = 7.4$  Hz, 6H).



Compound 20  
13C


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  165.37, 136.07, 71.64, 32.58, 31.66, 27.57,  
21.77, 13.69.








Compound 21  
13C




Compound 22  
1H

$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.27 (d,  $J = 2.4$  Hz, 4H), 3.34 – 3.26 (m, 4H), 2.22 (t,  $J = 2.5$  Hz, 1H), 1.69 – 1.60 (m, 4H), 1.45 – 1.36 (m, 4H), 1.27 (br s, 16H), 0.88 (t,  $J = 6.8$  Hz, 6H).




Compound 22  
13C




## Compound 23


<sup>1</sup>H

<sup>1</sup>H NMR (360 MHz, Chloroform-*d*)  $\delta$  4.27 (d,  $J = 2.5$  Hz, 2H), 3.36 – 3.22 (m, 4H), 2.21 (t,  $J = 2.5$  Hz, 1H), 1.64 (dq,  $J = 13.6, 6.5, 5.9$  Hz, 4H), 1.48 – 1.36 (m, 4H), 1.26 (s, 32H), 0.88 (t,  $J = 6.7$  Hz, 6H).






Compound 26  
DMSO, 300K, 13C, DUAL





S42







Compound 27  
DMSO, 298K, 13C, TXI















Compound 28  
DMSO, 298K, 13C, XI








Compound 31  
DMSO, 300K, 13C, TXI



Compound 31  
DMSO, 300K, COSY, TXI



f1 (ppm)

f2 (ppm)


S52




Compound 33

<sup>1</sup>H

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.26 – 4.14 (m, 2H), 3.76 – 3.56 (m, 16H), 3.26 (t, *J* = 7.3 Hz, 4H), 2.48 – 2.41 (m, 1H), 1.75 – 1.61 (m, 4H), 1.03 (t, *J* = 7.3 Hz, 6H).




Compound 33  
13C




Compound 34  
1H

$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.21 (d,  $J = 2.4$  Hz, 2H), 3.73 – 3.58 (m, 16H), 3.28 (t,  $J = 7.4$  Hz, 4H), 2.44 (t,  $J = 2.4$  Hz, 1H), 1.69 – 1.58 (m, 4H), 1.51 – 1.39 (m, 4H), 0.93 (t,  $J = 7.3$  Hz, 6H).




Compound 34  
13C



## Compound 35


<sup>1</sup>H

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.20 (d, *J* = 2.4 Hz, 2H), 3.73 – 3.59 (m, 16H), 3.31 – 3.24 (m, 4H), 2.44 (t, *J* = 2.3 Hz, 1H), 1.64 (dt, *J* = 15.1, 7.4 Hz, 4H), 1.42 (dt, *J* = 14.3, 7.2 Hz, 4H), 1.36 – 1.23 (m, 8H), 0.89 (t, *J* = 6.9 Hz, 6H).



Compound 35  
13C


$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  166.57, 135.74, 74.55, 70.64, 70.60, 70.43, 70.02, 69.12, 67.85, 58.40, 37.75, 31.85, 31.29, 30.44, 28.21, 22.51, 14.02.




## Compound 36

<sup>1</sup>H

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21 (d, *J* = 2.4 Hz, 2H), 3.72 – 3.59 (m, 16H), 3.32 – 3.23 (m, 4H), 2.43 (t, *J* = 2.4 Hz, 1H), 1.64 (dt, *J* = 15.0, 7.4 Hz, 4H), 1.46 – 1.36 (m, 4H), 1.30 (dt, *J* = 8.7, 5.1 Hz, 16H), 0.88 (t, *J* = 6.8 Hz, 6H).



Compound 36  
13C







Compound 37

<sup>1</sup>H

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.21 (d, *J* = 2.4 Hz, 2H), 3.73 – 3.57 (m, 16H), 3.27 (t, *J* = 7.4 Hz, 4H), 2.43 (t, *J* = 2.4 Hz, 1H), 1.69 – 1.59 (m, 4H), 1.40 (dd, *J* = 13.2, 7.5 Hz, 4H), 1.34 – 1.20 (m, 32H), 0.88 (t, *J* = 6.8 Hz, 6H).




Compound 37  
13C





Compound 38  
1H



<sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 5.51 (d, *J* = 4.9 Hz, 2H), 4.62 (dd, *J* = 7.9, 2.1 Hz, 2H), 4.35 – 4.27 (m, 4H), 4.21 (d, *J* = 2.0 Hz, 1H), 3.98 (t, *J* = 6.8 Hz, 2H), 3.73 – 3.57 (m, 16H), 3.57 – 3.34 (m, 4H), 2.45 (t, *J* = 2.4 Hz, 0H), 1.46 (d, *J* = 14.6 Hz, 12H), 1.32 (d, *J* = 3.9 Hz, 12H).




Compound 38  
13C








Compound 42  
DMSO, 298, 13C, TXI






Compound 44  
DMSO, 300K, HSQC, TXI








Compound 44  
DMSO, 300K, 13C, TXI










Compound 45  
DMSO, 298K, 13C, TXI












Compound 46  
DMSO, 298K, 13C, DUAL










Compound 52  
1H


<sup>1</sup>H NMR (360 MHz, Chloroform-*d*) δ 7.78 (s, 1H), 4.62 (s, 2H), 4.58 – 4.51 (m, 2H), 3.88 (t, *J* = 5.1 Hz, 2H), 3.76 – 3.70 (m, 2H), 3.67 (dd, *J* = 6.0, 2.7 Hz, 2H), 3.61 (q, *J* = 4.5 Hz, 8H), 3.53 (t, *J* = 6.6 Hz, 2H), 2.94 (s, 1H), 1.58 (dt, *J* = 14.5, 6.7 Hz, 2H), 1.37 (dq, *J* = 14.5, 7.3 Hz, 2H), 0.91 (t, *J* = 7.3 Hz, 3H).



Compound 52


<sup>1</sup>H

<sup>13</sup>C NMR (91 MHz, CDCl<sub>3</sub>) δ 145.32, 123.69, 72.57,  
70.59, 70.54, 70.47, 70.44, 70.32, 69.54, 64.29, 61.64,  
50.23, 31.72, 19.29, 13.89.




Compound 53  
1H

$^1\text{H}$  NMR (360 MHz, Chloroform-*d*)  $\delta$  7.79 (s, 1H), 4.62 (s, 2H), 4.55 (t,  $J = 5.0$  Hz, 2H), 3.92 – 3.84 (m, 2H), 3.76 – 3.69 (m, 2H), 3.69 – 3.57 (m, 10H), 3.52 (t,  $J = 6.7$  Hz, 2H), 3.09 (s, 1H), 1.66 – 1.53 (m, 2H), 1.41 – 1.24 (m, 6H), 0.88 (t,  $J = 6.6$  Hz, 3H).




Compound 53  
13C

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  145.23, 123.79, 72.56,  
70.78, 70.52, 70.45, 70.35, 70.22, 69.47, 64.20, 61.53, 50.18,  
31.63, 29.56, 25.74, 22.56, 14.01.



Compound 54  
1H


$^1\text{H}$  NMR (360 MHz, Chloroform-*d*)  $\delta$  7.77 (s, 1H), 4.62 (s, 2H), 4.55 (t,  $J=5.0$  Hz, 2H), 3.95–3.82 (m, 2H), 3.75–3.70 (m, 2H), 3.69–3.56 (m, 10H), 3.51 (t,  $J=6.7$  Hz, 2H), 2.94 (s, 1H), 1.66–1.51 (m, 2H), 1.39–1.18 (m, 10H), 0.87 (t,  $J=6.7$  Hz, 3H).



Compound 54


<sup>13</sup>C

<sup>13</sup>C NMR (91 MHz, CDCl<sub>3</sub>) δ 145.32, 123.70, 72.58,  
70.84, 70.61, 70.55, 70.46, 70.34, 69.55, 64.31, 61.65,  
50.23, 31.83, 29.68, 29.45, 29.26, 26.14, 22.66, 14.09.




S84






Compound 55  
13C

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  72.63, 70.90, 70.60, 70.54, 70.44, 70.30, 69.57, 64.32, 61.65, 50.27, 31.99, 29.76, 29.71, 29.66, 29.64, 29.55, 29.42, 29.38, 26.17, 22.74, 14.17.



## Compound 56

<sup>1</sup>H


Compound 56  
13C

$^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ )  $\delta$  145.37, 123.68, 74.64, 70.66, 70.63, 70.55, 70.53, 70.47, 69.56, 69.17, 64.34, 58.45, 50.30, 31.78, 19.36, 13.97.




Compound 57  
1H

<sup>1</sup>H NMR (400 MHz, Chloroform-*d*) δ 7.73 (s, 1H), 4.61 (s, 2H), 4.54 (t, *J* = 5.1 Hz, 2H), 4.19 (d, *J* = 2.3 Hz, 2H), 3.88 (t, *J* = 5.1 Hz, 2H), 3.73 – 3.59 (m, 12H), 3.51 (t, *J* = 6.7 Hz, 2H), 2.44 (t, *J* = 2.4 Hz, 1H), 1.59 (p, *J* = 6.9 Hz, 2H), 1.40 – 1.21 (m, 6H), 0.88 (t, *J* = 6.7 Hz, 3H).




Compound 57  
13C




Compound 58  
1H

$^1\text{H NMR}$  (360 MHz, Chloroform- $d$ )  $\delta$  7.74 (s, 1H), 4.61 (s, 2H), 4.54 (t,  $J = 5.1$  Hz, 2H), 4.19 (d,  $J = 2.4$  Hz, 2H), 3.92 – 3.84 (m, 2H), 3.73 – 3.57 (m, 12H), 3.51 (t,  $J = 6.7$  Hz, 2H), 2.44 (t,  $J = 2.3$  Hz, 1H), 1.59 (dt,  $J = 14.4$ , 6.8 Hz, 2H), 1.38 – 1.21 (m, 10H), 0.88 (t,  $J = 6.8$  Hz, 3H).




Compound 58  
13C







Compound 59  
1H

$^1\text{H}$  NMR (360 MHz, Chloroform- $d$ )  $\delta$  7.73 (s, 1H), 4.62 (s, 2H), 4.54 (t,  $J = 5.1$  Hz, 2H), 4.20 (d,  $J = 2.4$  Hz, 2H), 3.94 – 3.82 (m, 2H), 3.78 – 3.57 (m, 12H), 3.51 (t,  $J = 6.7$  Hz, 2H), 2.44 (t,  $J = 2.4$  Hz, 1H), 1.59 (p,  $J = 6.6$  Hz, 2H), 1.26 (s, 14H), 0.88 (t,  $J = 6.7$  Hz, 3H).




Compound 59  
13C






Compound 60  
DMSO, 298K, 13C, TXI



S96


Compound 61  
DMSO, 298K, HSQC, TXI




f1 (ppm)


S97

Compound 61  
DMSO, 298K, 13C, TXI







Compound 62  
DMSO, 298K, 13C, DUAL









Compound 63  
DMSO, 13C, TXI





S102




Compound 73  
DMSO, 298K, 13C, TXI








Compound 75  
DMSO, 298K, 13C, TXI



Compound 75  
DMSO, 298K, HMBC, TXI




f1 (ppm)

f2 (ppm)

S108




Compound 75  
DMSO, 298K, HSQC, TXI




f1 (ppm)

f2 (ppm)


S109





Compound 76  
DMSO, 298K, 13C, TXI



S111







f1 (ppm)

f2 (ppm)

S114

Compound 79  
DMSO, 298K HSQC, TXI

